ERBB2 and gastric cancer: Using tissue microarrays from 528 consecutive GC patients, we intended to compare the novel trastuzumab IHC with the previously used HER2 assessment methods to determine whether trastuzumab IHC intensity scores were associated with the overall prognosis of gastric cancer.